卫光生物拟对下属单采血浆站增资

Core Insights - The company, Weigao Biology, announced plans to increase capital in its subsidiaries, Wanning Weigao Plasma Collection Co., Ltd. and Ankang Weigao Plasma Collection Station Co., Ltd., by 15 million yuan and 40 million yuan respectively to enhance plasma collection efficiency and improve financial structure [1][1][1] - The company aims to strengthen its international brand influence and advance its international strategy by signing a blood product technology cooperation contract, which includes a technology licensing fee of 12 million USD and a technology transfer service fee of 4 million USD, totaling approximately 113.21 million yuan [1][1][1] Group 1 - The company plans to invest a total of 55 million yuan in its plasma collection subsidiaries to solidify its plasma business foundation and ensure stable plasma supply [1] - The technology cooperation contract is part of the company's strategy to enhance its international presence and includes significant financial commitments [1][1] Group 2 - The capital increase is expected to accelerate the construction of plasma stations and improve operational efficiency [1] - The total financial commitment for the technology cooperation amounts to 16 million USD, reflecting the company's focus on technological advancement in blood products [1][1]